Abstracts tagged "Cancer"

Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 719 • 2015 ACR/ARHP Annual Meeting
Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
Basile Tessier Cloutier¹, Pedro Farinha², Sasha Bernatsky³, Eva Baecklund⁴, Ann E. Clarke⁵, Rosalind Ramsey-Goldman⁶, Randy Gascoyne⁷ and SLICC Investigators, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Pathology, BC Cancer Agency, Vancouver, BC, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden, ⁵Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ⁶Fsm # M300, SLICC, Chicago, IL, ⁷Pathology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Background/Purpose: SLE has been consistently associated with an increased incidence of malignant lymphoma, especially the DLBCL subtype. Since the last WHO classification of 2008 DLBCL…
Abstract Number: 763 • 2015 ACR/ARHP Annual Meeting
Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma
Sasha Bernatsky^1,2, John Spinelli³, Patrick M. Gaffney⁴, Karin E Smedby⁵, Rosalind Ramsey-Goldman⁶, Sophia Wang⁷ and Ann E. Clarke⁸, ¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ³School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Fsm # M300, Northwestern University, Chicago, IL, ⁷Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁸Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: The determinants behind the increased risk of non-Hodgkin Lymphoma (NHL) in systemic lupus (SLE) are unclear. The most common type of NHL in SLE…
Abstract Number: 955 • 2015 ACR/ARHP Annual Meeting
Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Omid Zahedi Niaki¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Rae S.M. Yeung⁴, Kristen Hayward⁵, Kiem Oen⁶, Ciarán M. Duffy⁷, Alan M. Rosenberg⁸, Kathleen O'Neil⁹, Emily von Scheven¹⁰, Laura Schanberg¹¹, Jeremy Labrecque¹², Jennifer LF Lee¹³ and Sasha Bernatsky¹⁴, ¹Medicine, McGill University, Montreal, QC, Canada, ²Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Pediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁵Pediatric Rheumatology, University of Washington & SCH, Seattle, WA, ⁶Department of Pediatrics and Child Health, University of Manitoba; Head, Section of Pediatric Rheumatology, Children’s Hospital, University of Manitoba, The Children`s Hospital Foundation of Manitoba, Winnipeg, MB, Canada, ⁷Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁸Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁹Pediatric Rheumatology, RIley Hospital for Children, Indianapolis, IN, ¹⁰Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA, ¹¹Pediatrics, Duke Medical Center, Durham, NC, ¹²Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹³Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ¹⁴Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Given suspected links between inflammation and malignancy, several groups have attempted to elucidate the baseline risk of cancer in various inflammatory or autoimmune conditions, including rheumatoid arthritis,…
Abstract Number: 1684 • 2015 ACR/ARHP Annual Meeting
Malignancies in Patients with Incident Psoriatic Arthritis 1970-2008 in Relation to a Comparator Cohort: A Population-Based Case-Control Study
Katelynn Wilton^1,2, Brittny T. Major³, Cynthia Crowson³ and Eric L. Matteson⁴, ¹Medical Scientist Training Program, Mayo Clinic, Rochester, MN, ²Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ³Biostatistics, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: In psoriatic arthritis (PsA), misdirected inflammation and therapeutic use of immunosuppressants causes global immune compromise. Similar immunocompromised states, as in rheumatoid arthritis and psoriasis…
Abstract Number: 3236 • 2015 ACR/ARHP Annual Meeting
Circulating Cytokine/Chemokine Concentrations Predict Cancer Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Jeremy Sokolove², William H. Robinson³, Geoffrey M. Thiele⁴, Apar K. Ganti⁵, Harlan Sayles⁶, Kaleb Michaud⁷, Liron Caplan⁸, Lisa A. Davis⁸, Grant W. Cannon⁹, Brian Sauer¹⁰, E. Blair Solow¹¹, Andreas Reimold¹², Gail S. Kerr¹³, Pascale Schwab¹⁴, Joshua F. Baker¹⁵ and Ted R. Mikuls¹⁶, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Oncology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁸Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹²Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹³VAMC, Georgetown University, Washington, DC, ¹⁴Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁵Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammation and the dysregulated expression of pro-inflammatory cytokines / chemokines (CK). Chronic inflammation has also been implicated…
Abstract Number: 3261 • 2015 ACR/ARHP Annual Meeting
Examining the Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients with Breast Cancer
Dhaval Shah¹, Ram Hirpara¹, Laura K. Hummers¹, Fredrick M. Wigley², Virginia D. Steen³, Robyn T. Domsic⁴ and Ami A. Shah⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Radiation oncologists are hesitant to treat scleroderma (SSc) patients with cancer due to concerns about triggering exaggerated fibrosis. In this study, we examined SSc…
Abstract Number: 818 • 2014 ACR/ARHP Annual Meeting
Incident Rheumatoid Arthritis and Risk of Mortality Among Women Followed Prospectively from 1976 to 2010 in the Nurses’ Health Study
Jeffrey A. Sparks¹, Shun-Chiao Chang^1,2, Katherine P. Liao¹, Bing Lu¹, Daniel H. Solomon¹, Karen H. Costenbader¹ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose RA has been associated with increased mortality compared to general population estimates. Previous studies were limited due to the inability to directly compare RA…
Abstract Number: 2791 • 2014 ACR/ARHP Annual Meeting
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2198 • 2014 ACR/ARHP Annual Meeting
The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing?
Zsolt Kulcsar¹, Clinton Morgan², Peter Kaufman³, Jonathan Jones⁴ and William Rigby⁵, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Hematology/Oncology, Dartmouth Hitchcock Medical Center, lebanon, NH, ⁴Rheumatology Clinic, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ⁵Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH
Background/Purpose: Aromatase Inhibitor (AI) therapy is the most effective hormonal treatment in post-menopausal estrogen receptor (ER) positive breast cancer. These patients may be seen by…
Abstract Number: 1071 • 2014 ACR/ARHP Annual Meeting
What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer?
Julia Simard^1,2, Sara Ekberg³, Anna Johansson⁴ and Johan Askling^2,5, ¹Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ²Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept of Medical Epidemiology of Biostatistic, Karolinska Institutet, Stockholm, Sweden, ⁴Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging evidence links inflammation and immune-competence to cancer progression and outcome. The few studies addressing cancer survival in the context of systemic inflammation,…
Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Pratibha Nayak¹, Ruili Luo², Linda Elting² and Maria E. Suarez-Almazor³, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…
Abstract Number: 1075 • 2014 ACR/ARHP Annual Meeting
Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus on Immunosuppressive Drugs
Candace H. Feldman¹, Jun Liu², Sarah Feldman³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomavirus (HPV) is the most common sexually transmitted disease in the US and the main cause of high-grade cervical dysplasia and cervical cancer.…
Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Pauline Raaschou¹, Julia F Simard², Charlotte Asker-Hagelberg³, Johan Askling⁴ and the ARTIS Study group⁵, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, ⁴Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].